These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 8567179)
21. Local structural properties of the V3 loop of Thailand HIV-1 isolate. Andrianov AM J Biomol Struct Dyn; 2002 Jun; 19(6):973-89. PubMed ID: 12023800 [TBL] [Abstract][Full Text] [Related]
22. The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1. Zolla-Pazner S; Zhong P; Revesz K; Volsky B; Williams C; Nyambi P; Gorny MK AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1254-8. PubMed ID: 15588347 [TBL] [Abstract][Full Text] [Related]
24. [Study of conformational homology for the HIV-1 gpi20 V3 loop. structural analysis of the HIV-RF and HIV-Thailand viral strains]. Andrianov AM Biomed Khim; 2006; 52(5):448-57. PubMed ID: 17180919 [TBL] [Abstract][Full Text] [Related]
25. Conformational model for the consensus V3 loop of the envelope protein gp120 of HIV-1 in a 20% trifluoroethanol/water solution. Vranken WF; Fant F; Budesinsky M; Borremans FA Eur J Biochem; 2001 May; 268(9):2620-8. PubMed ID: 11322882 [TBL] [Abstract][Full Text] [Related]
26. The principal neutralizing determinant of HIV-1 located in V3 of gp120 forms a 12-residue loop by internal hydrophobic interactions. Zvi A; Kustanovich I; Hayek Y; Matsushita S; Anglister J FEBS Lett; 1995 Jul; 368(2):267-70. PubMed ID: 7543061 [TBL] [Abstract][Full Text] [Related]
27. Solid-state NMR evidence for an antibody-dependent conformation of the V3 loop of HIV-1 gp120. Weliky DP; Bennett AE; Zvi A; Anglister J; Steinbach PJ; Tycko R Nat Struct Biol; 1999 Feb; 6(2):141-5. PubMed ID: 10048925 [TBL] [Abstract][Full Text] [Related]
28. Structural comparison of a 15 residue peptide from the V3 loop of HIV-1IIIb and an O-glycosylated analogue. Huang X; Smith MC; Berzofsky JA; Barchi JJ FEBS Lett; 1996 Sep; 393(2-3):280-6. PubMed ID: 8814305 [TBL] [Abstract][Full Text] [Related]
29. Crystal structure of a human rhinovirus that displays part of the HIV-1 V3 loop and induces neutralizing antibodies against HIV-1. Ding J; Smith AD; Geisler SC; Ma X; Arnold GF; Arnold E Structure; 2002 Jul; 10(7):999-1011. PubMed ID: 12121655 [TBL] [Abstract][Full Text] [Related]
30. NMR-derived solution conformations of a hybrid synthetic peptide containing multiple epitopes of envelope protein gp120 from the RF strain of human immunodeficiency virus. de Lorimier R; Moody MA; Haynes BF; Spicer LD Biochemistry; 1994 Mar; 33(8):2055-62. PubMed ID: 7509632 [TBL] [Abstract][Full Text] [Related]
31. Conformational rearrangements required of the V3 loop of HIV-1 gp120 for proteolytic cleavage and infection. Johnson ME; Lin Z; Padmanabhan K; Tulinsky A; Kahn M FEBS Lett; 1994 Jan; 337(1):4-8. PubMed ID: 8276110 [TBL] [Abstract][Full Text] [Related]
32. Molecular switch for alternative conformations of the HIV-1 V3 region: implications for phenotype conversion. Rosen O; Sharon M; Quadt-Akabayov SR; Anglister J Proc Natl Acad Sci U S A; 2006 Sep; 103(38):13950-5. PubMed ID: 16966601 [TBL] [Abstract][Full Text] [Related]
33. Discovery of novel anti-HIV-1 agents based on a broadly neutralizing antibody against the envelope gp120 V3 loop: a computational study. Andrianov AM; Kashyn IA; Tuzikov AV J Biomol Struct Dyn; 2014 Dec; 32(12):1993-2004. PubMed ID: 24251545 [TBL] [Abstract][Full Text] [Related]
34. Stabilization of unusual structures in peptides using alpha,beta-dehydrophenylalanine: crystal and solution structures of Boc-Pro-DeltaPhe-Val-DeltaPhe-Ala-OMe and Boc-Pro-DeltaPhe-Gly-DeltaPhe-Ala-OMe. Mathur P; Ramagopal UA; Ramakumar S; Jagannathan NR; Chauhan VS Biopolymers; 2006; 84(3):298-309. PubMed ID: 16411186 [TBL] [Abstract][Full Text] [Related]
35. A cis proline turn linking two beta-hairpin strands in the solution structure of an antibody-bound HIV-1IIIB V3 peptide. Tugarinov V; Zvi A; Levy R; Anglister J Nat Struct Biol; 1999 Apr; 6(4):331-5. PubMed ID: 10201400 [TBL] [Abstract][Full Text] [Related]
36. Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity. Stanfield RL; Gorny MK; Zolla-Pazner S; Wilson IA J Virol; 2006 Jun; 80(12):6093-105. PubMed ID: 16731948 [TBL] [Abstract][Full Text] [Related]
37. Restricted variable residues in the C-terminal segment of HIV-1 V3 loop regulate the molecular anatomy of CCR5 utilization. Hu Q; Napier KB; Trent JO; Wang Z; Taylor S; Griffin GE; Peiper SC; Shattock RJ J Mol Biol; 2005 Jul; 350(4):699-712. PubMed ID: 15964018 [TBL] [Abstract][Full Text] [Related]
38. Structural analysis of the envelope gp120 V3 loop for some HIV-1 variants circulating in the countries of Eastern Europe. Andrianov AM; Kornoushenko YV; Anishchenko IV; Eremin VF; Tuzikov AV J Biomol Struct Dyn; 2013; 31(7):665-83. PubMed ID: 22888999 [TBL] [Abstract][Full Text] [Related]
39. A model of a gp120 V3 peptide in complex with an HIV-neutralizing antibody based on NMR and mutant cycle-derived constraints. Zvi A; Tugarinov V; Faiman GA; Horovitz A; Anglister J Eur J Biochem; 2000 Feb; 267(3):767-79. PubMed ID: 10651813 [TBL] [Abstract][Full Text] [Related]
40. Positioning of positively charged residues in the V3 loop correlates with HIV type 1 syncytium-inducing phenotype. Bhattacharyya D; Brooks BR; Callahan L AIDS Res Hum Retroviruses; 1996 Jan; 12(2):83-90. PubMed ID: 8834457 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]